T Cell-Expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment

Journal of Bone and Mineral Research

Volumn 30, Issue 4, 2015, Pages 695-705

  Robinson, Jerid W ^a   Li, Jau Yi ^a   Walker, Lindsey D ^a   Tyagi, Abdul Malik ^a   Reott, Michael A ^a   Yu, Mingcan ^a   Adams, Jonathan ^a   Weitzmann, M Neale ^a,b   Pacifici, Roberto ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

BM; Bone Marrow; OB; Osteoblast; Parathyroid Hormone; PPR; PTH; PTH PTHRP Receptor; SC; Stromal Cell

Indexed keywords

ALKALINE PHOSPHATASE; ALYL HYDROCARBON RECEPTOR; AXIN2 PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CASPASE 3; CD40 LIGAND; COLLAGEN TYPE 1; CYSTEIN RICH PROTEIN 61; MESSENGER RNA; NAKED CUTICLE 2 HMOLOG; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROTEIN; SIALOPROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; WNT10B PROTEIN; ANABOLIC AGENT; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE EXPRESSION; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRABECULAR BONE; TREATMENT RESPONSE; WNT SIGNALING PATHWAY; ANIMAL; BONE; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; CD40 LIGAND; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARATHYROID HORMONE; T-LYMPHOCYTES;

EID: 84925392993     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2394     Document Type: Article

References (70)

1. Zaidi M,. Skeletal remodeling in health and disease. Nat Med. 2007; 13: 791-801.
2. Calvi LM, Sims NA, Hunzelman JL, et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001; 107: 277-86.
3. Lanske B, Amling M, Neff L, Guiducci J, Baron R, Kronenberg HM,. Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J Clin Invest. 1999; 104: 399-407.
4. Qin L, Raggatt LJ, Partridge NC,. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15: 60-5.
5. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009; 10: 229-40.
6. Cho SW, Soki FN, Koh AJ, et al. Osteal macrophages support physiologic skeletal remodeling,anabolic actions of parathyroid hormone in bone. Proc Natl Acad Sci U S.A. 2014 Jan 28; 111 (4): 1545-50.
7. Powell WF Jr, Barry KJ, Tulum I, et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol. 2011; 209: 21-32.
8. Saini V, Marengi DA, Barry KJ, et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem. 2013; 288: 20122-34.
9. Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O'Brien CA,. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone. 2014;66C 146-54.
10. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21: 366-73.
11. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 855-64.
12. Dobnig H, Turner RT,. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138: 4607-612.
13. Dobnig H, Turner RT,. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 3632-8.
14. Nishida S, Yamaguchi A, Tanizawa T, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994; 15: 717-23.
15. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK,. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 2008; 42: 806-18.
16. Meng XW, Liang XG, Birchman R, et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res. 1996; 11: 421-9.
17. Schmidt IU, Dobnig H, Turner RT,. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology. 1995; 136: 5127-34.
18. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC,. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439-46.
19. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278: 50259-72.
20. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S,. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem. 2005; 280: 41342-51.
21. Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell. 2010; 7: 571-80.
22. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15: 757-65.
23. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002; 17: 1570-8.
24. Yamaguchi M, Ogata N, Shinoda Y, et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology. 2005; 146: 2620-8.
25. Jilka RL,. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40: 1434-46.
26. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002; 157: 303-14.
27. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001; 142: 4047-54.
28. Bodine PV, Komm BS,. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord. 2006; 7: 33-9.
29. Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147: 2583-90.
30. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005; 96: 1212-30.
31. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-64.
32. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968-79.
33. Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007; 282: 33086-97.
34. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-58.
35. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577-83.
36. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007; 38: 261-9.
37. Baron R, Kneissel M,. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19: 179-92.
38. Guo J, Liu M, Yang D, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010; 11: 161-71.
39. Bedi B, Li JY, Tawfeek H, et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A 2012; 109: E725-33.
40. Grewal IS, Flavell RA,. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998; 16: 111-35.
41. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ,. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22: 307-28.
42. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002; 8: 247-52.
43. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR,. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A 2003; 100: 12367-71.
44. Zirlik A, Maier C, Gerdes N, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 2007; 115: 1571-80.
45. Leveille C, Bouillon M, Guo W, et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem. 2007; 282: 5143-51.
46. Grammer AC, Lipsky PE,. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv Immunol. 2000; 76: 61-178.
47. Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF,. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology. 2003; 144: 1761-9.
48. Grewal IS, Flavell RA,. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996; 153: 85-106.
49. Lopez-Granados E, Temmerman ST, Wu L, et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci U S A 2007; 104: 5056-61.
50. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007; 109: 3839-48.
51. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 2008; 8: 132-45.
52. Li JY, Tawfeek H, Bedi B, et al. Ovariectomy disregulates osteoblast,osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A 2011; 108: 768-73.
53. Li JY, Adams J, Calvi LM, Lane TF, Weitzmann MN, Pacifici R,. Ovariectomy expands murine short-term hemopoietic stem cell function through T cell expressed CD40L and Wnt10B. Blood. 2013; 122: 2346-57.
54. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One. 2010; 5: e12290.
55. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
56. Li JY, Walker LD, Tyagi AM, Adams J, Weitzmann MN, Pacifici R,. The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res. 2014; 29: 43-54.
57. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR,. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol. 2002; 168: 744-54.
58. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001; 97: 2777-83.
59. Jackson A, Vayssiere B, Garcia T, et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone. 2005; 36: 585-98.
60. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R,. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem. 1996; 271: 28890-7.
61. Drake MT, Srinivasan B, Modder UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone. 2011; 49: 349-55.
62. Hardiman G, Albright S, Tsunoda J, McClanahan T, Lee F,. The mouse Wnt-10B gene isolated from helper T cells is widely expressed and a possible oncogene in BR6 mouse mammary tumorigenesis. Gene. 1996; 172: 199-205.
63. Kramer I, Keller H, Leupin O, Kneissel M,. Does osteocytic SOST suppression mediate PTH bone anabolism. Trends Endocrinol Metab. 2010; 21: 237-44.
64. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P,. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med. 2003; 9: 526-34.
65. Zhao E, Xu H, Wang L, et al. Bone marrow and the control of immunity. Cell Mol Immunol. 2012; 9: 11-9.
66. Di Rosa F, Pabst R,. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 2005; 26: 360-6.
67. Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011; 474: 216-9.
68. Pacifici R,. T cells: critical bone regulators in health and disease. Bone. 2010; 47: 461-71.
69. Li JY, Adams J, Calvi LM, et al. PTH expands short-term murine hemopoietic stem cells through T cells. Blood. 2012; 120: 4352-62.
70. Monteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A,. Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood. 2005; 105: 1484-91.